ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives $7.14 Average Target Price from Brokerages

Shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) have been assigned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $7.1429.

Several equities research analysts have recently weighed in on the company. Chardan Capital reiterated a “buy” rating and issued a $4.00 price target on shares of ProQR Therapeutics in a report on Tuesday, November 4th. Zacks Research raised ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research note on Wednesday, October 8th.

ProQR Therapeutics Trading Down 0.7%

ProQR Therapeutics stock opened at $2.19 on Monday. ProQR Therapeutics has a 12-month low of $1.07 and a 12-month high of $3.10. The firm has a 50-day moving average price of $2.35 and a 200-day moving average price of $2.23. The firm has a market capitalization of $230.84 million, a PE ratio of -4.67 and a beta of 0.17.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.02). The firm had revenue of $3.38 million for the quarter, compared to the consensus estimate of $7.05 million. ProQR Therapeutics had a negative net margin of 273.20% and a negative return on equity of 58.70%. As a group, sell-side analysts predict that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ProQR Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Palo Alto Investors LP purchased a new stake in ProQR Therapeutics in the 3rd quarter valued at about $402,000. Citadel Advisors LLC raised its stake in shares of ProQR Therapeutics by 73.2% during the third quarter. Citadel Advisors LLC now owns 657,012 shares of the biopharmaceutical company’s stock valued at $1,399,000 after acquiring an additional 277,749 shares in the last quarter. Boothbay Fund Management LLC boosted its holdings in shares of ProQR Therapeutics by 10.8% in the third quarter. Boothbay Fund Management LLC now owns 248,290 shares of the biopharmaceutical company’s stock valued at $529,000 after purchasing an additional 24,160 shares during the period. ArrowMark Colorado Holdings LLC grew its stake in ProQR Therapeutics by 3.9% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,246,234 shares of the biopharmaceutical company’s stock worth $2,654,000 after purchasing an additional 46,596 shares in the last quarter. Finally, Raymond James Financial Inc. grew its stake in ProQR Therapeutics by 15.2% in the third quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 14,549 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.